3 Firms Steer Galapagos' Plan To Spin Off New Drug Company <https://www.law360.com/health/articles/2281359?nl_pk=0f5983ea-0173-4e74-85e2-7daeb9cfc0fc&utm_source=newsletter&utm_medium=email&utm_campaign=health&utm_content=2025-01-09&read_main=1&nlsidx=0&nlaidx=13> By Tom Zanki Belgian biotechnology firm Galapagos NV said Wednesday that it will spin off certain operations into a second company focused on developing innovative medicines with about €2.45 billion ($2.5 billion) in cash to start, while Galapagos in turn focuses on cell therapies, through a deal guided by three law firms. Read full article » <https://www.law360.com/health/articles/2281359?nl_pk=0f5983ea-0173-4e74-85e2-7daeb9cfc0fc&utm_source=newsletter&utm_medium=email&utm_campaign=health&utm_content=2025-01-09&read_more=1&nlsidx=0&nlaidx=13> | Save to favorites » <https://www.law360.com/health/articles/2281359?nl_pk=0f5983ea-0173-4e74-85e2-7daeb9cfc0fc&utm_source=newsletter&utm_medium=email&utm_campaign=health&utm_content=2025-01-09&read_later=1&nlsidx=0&nlaidx=13>